Biological Safety Testing Services Market Size & Growth Forecast 2027–2036, By Segments (End-use, Application, Services), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Biological Safety Testing Services Market size stood at USD 4.7 billion in 2026 and is predicted to grow at a 12.16% CAGR from 2027 to 2036, crossing USD 14.81 billion by 2036. The industry revenue for 2027 is calculated at USD 5.18 billion.
Get more details on this report
Request Free Sample ReportBiological Safety Testing Services Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with a 35.09% share driven by strong biopharma activity, established outsourcing networks, and stringent regulatory testing for biologics, vaccines, and advanced therapies.
- Asia Pacific grows at 12.99% CAGR due to expanding biologics manufacturing, increased outsourcing, and development of cost-efficient testing infrastructure supporting regulatory and production needs.
Segment Momentum
- Biopharmaceutical companies lead because routine drug development, manufacturing, batch release, and regulatory compliance require consistent biological safety testing throughout production workflows.
- Cell and gene therapy is growing fastest because its complex products require specialized safety validation, stricter manufacturing controls, and greater reliance on biological safety testing services during development and production.
Market Expansion Drivers
- Expanding biologics and biosimilars pipelines increasing demand for regulatory-compliant safety testing services.
- Growing cell and gene therapy development accelerating microbial and viral contamination assessments.
- Increasing outsourcing to CROs and CDMOs improving access to specialized biological testing capabilities.
Leading Market Participants
- Prominent players in the biological safety testing services market include Charles River Laboratories International, Inc. (United States), Lonza Group AG (Switzerland), Thermo Fisher Scientific Inc. (United States), Merck KGaA (Germany), Eurofins Scientific SE (Luxembourg), SGS SA (Switzerland), WuXi AppTec Co., Ltd. (China), Sartorius AG (Germany), bioMérieux SA (France), Toxikon Corporation (United States).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 4.7 billion
- 2027 Estimated Market Size: USD 5.18 billion.
- Projected Market Size: USD 14.81 billion by 2036
- Growth Forecast: 12.16% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Biopharmaceutical Companies (End-use) | Vaccine & Therapeutics (Application) | Bioburden Testing Services (Services)
- Emerging Opportunity Segment: Academic and Research Institutions (End-use) | Cell and Gene Therapy (Application) | Cell Line Authentication and Characterization Tests (Services)
Market Growth Drivers and Industry Trends
Expanding biologics and biosimilars pipelines increasing demand for regulatory-compliant safety testing services
The biological safety testing services market is gaining momentum as pharmaceutical developers expand biologics and biosimilars pipelines that require rigorous evaluation before clinical and commercial use. These products involve complex biological components and manufacturing processes, creating a need to assess potential contamination, impurities, and other safety risks in accordance with regulatory requirements. As development programs progress through increasingly demanding stages of validation, manufacturers require specialized testing capabilities to demonstrate product quality and support regulatory submissions.
Growing cell and gene therapy development accelerating microbial and viral contamination assessments
Rapid development of cell and gene therapies is creating new requirements within the biological safety testing services market for comprehensive microbial and viral contamination assessments. These advanced therapies often involve living cells, biological materials, and complex production workflows that can introduce specific safety considerations during manufacturing and processing. Testing for adventitious agents, microbial contamination, and viral safety helps developers evaluate product integrity and manage risks associated with biological production systems, particularly as more therapies move through development and commercialization pathways.
Increasing outsourcing to CROs and CDMOs improving access to specialized biological testing capabilities
Outsourcing to contract research organizations and contract development and manufacturing organizations is strengthening the biological safety testing services market by allowing pharmaceutical and biotechnology companies to access specialized testing infrastructure without establishing extensive internal capabilities. External providers can support complex analytical and safety assessments through dedicated expertise, validated processes, and laboratory resources. This approach can help developers manage testing requirements more efficiently while concentrating internal resources on drug discovery, development, and manufacturing activities.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding biologics and biosimilars pipelines increasing demand for regulatory-compliant safety testing services | 2.40% | High | North America, Europe | High | Near Term |
| Growing cell and gene therapy development accelerating microbial and viral contamination assessments | 2.10% | High | North America, Asia Pacific | High | Mid Term |
| Increasing outsourcing to CROs and CDMOs improving access to specialized biological testing capabilities | 1.60% | Moderate | Asia Pacific, Europe | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America dominated the biological safety testing services market, accounting for a 35.09% share in 2026, supported by a mature biopharmaceutical ecosystem, stringent quality and safety expectations, and widespread adoption of advanced biologics and pharmaceutical development programs. The region benefits from strong demand for testing services across vaccine development, cell and gene therapies, biologics manufacturing, and clinical research, where comprehensive evaluation of contamination risks, viral safety, sterility, and product quality is essential. Well-established regulatory frameworks encourage manufacturers and developers to incorporate rigorous biological safety assessments throughout product development and commercialization, sustaining demand for specialized testing capabilities. In addition, sophisticated laboratory infrastructure, established contract research and testing networks, and high levels of investment in biopharmaceutical innovation reinforce the region's market position. Increasingly complex biological products are also creating demand for specialized analytical expertise, while outsourcing trends allow pharmaceutical and biotechnology organizations to access advanced testing capabilities without expanding internal laboratory infrastructure. These factors collectively support North America's continued leadership in biological safety testing services.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is positioned as the fastest-growing region, driven by the expansion of pharmaceutical and biotechnology manufacturing, increasing clinical research activity, and growing adoption of internationally aligned quality and safety practices. The region's expanding biologics pipeline is generating greater requirements for testing throughout discovery, development, manufacturing, and quality control, particularly as manufacturers strengthen capabilities for complex biological products. Rising healthcare investment and the development of domestic biopharmaceutical infrastructure are encouraging broader use of specialized laboratory services, while regulatory modernization is gradually increasing the emphasis on systematic biological safety evaluation. The growing presence of contract development and manufacturing activities is another important contributor, as manufacturers serving both domestic and international markets require dependable testing processes that support product quality and regulatory compliance. Demand is further supported by expanding research capacity, greater awareness of contamination and biosafety risks, and the increasing need to demonstrate product consistency across sophisticated production environments. Together, these developments are creating a strong foundation for sustained expansion of biological safety testing services across Asia Pacific.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Regulatory Testing ExcellenceGermany emphasizes biological safety testing services that align with stringent manufacturing and regulatory quality requirements. German laboratories continue strengthening specialized testing capabilities for biologics while supporting efficient product release and development activities.
France 🇫🇷
Specialized Laboratory CapabilitiesFrance is reinforcing biological safety testing through specialized laboratory expertise supporting biologics, vaccines, and innovative therapies. French service providers are improving testing efficiency while maintaining rigorous quality standards required throughout product development.
Italy 🇮🇹
Compliance Testing ServicesItaly is strengthening biological safety testing services by expanding laboratory capabilities for pharmaceutical and biotechnology applications. Italian testing providers are focusing on reliable contamination detection, product characterization, and regulatory compliance throughout biologics manufacturing.
Japan 🇯🇵
Biologics Validation SupportJapan is expanding biological safety testing capacity to meet growing demand for biologics and regenerative medicine products. Japanese testing organizations are investing in validated analytical methods that improve consistency across development and quality assurance processes.
South Korea 🇰🇷
Contract Testing ExpansionSouth Korea is increasing biological safety testing services alongside growth in domestic biopharmaceutical manufacturing. South Korean laboratories are broadening specialized testing portfolios to support product safety verification, regulatory expectations, and international development programs.
United States 🇺🇸
Biopharma Quality AssuranceThe U.S. biological safety testing services market focuses on comprehensive quality testing for biologics, vaccines, and advanced therapeutics. U.S. service providers are expanding analytical capabilities to support regulatory compliance and increasingly complex product development pipelines.
Segment Leadership and Growth Trends
Biological Safety Testing Services Market Share (%), by End-use, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportEnd-use Segment Analysis: Biopharmaceutical Companies (Largest Segment) vs Academic and Research Institutions (Fastest-Growing Segment)
Biopharmaceutical companies held the largest share in 2026, driven by the extensive need for biological safety testing throughout the development, manufacturing, and commercialization of complex biologics. These organizations require rigorous evaluation of products and production processes to identify contamination risks and demonstrate compliance with applicable quality and safety requirements. Expanding development pipelines for biologics and increasingly sophisticated manufacturing processes are creating sustained demand for specialized testing expertise. Outsourcing also enables companies to access advanced analytical capabilities while maintaining greater flexibility and efficiency across development programs.
Academic and research institutions are expected to be the fastest-growing end-use segment as scientific research increasingly focuses on advanced biological systems, novel therapeutic approaches, and translational medicine. These institutions require specialized safety testing support for experimental materials and research programs involving complex biological products. Growth in collaborative research, expanding life sciences infrastructure, and greater emphasis on moving laboratory discoveries toward clinical development are strengthening demand. Access to external testing services also allows research organizations to use specialized expertise and technologies without building all capabilities internally.
Application Segment Analysis: Vaccine & Therapeutics (Largest Segment) vs Cell and Gene Therapy (Fastest-Growing Segment)
The vaccine & therapeutics application segment held the largest share in 2026, reflecting the extensive safety testing requirements associated with biological products intended for human use. Developers must evaluate materials and manufacturing processes for potential contaminants and other biological safety risks across multiple stages of product development. The continued expansion of biologic medicines and vaccine development programs is supporting sustained demand for comprehensive testing services. Increasing regulatory scrutiny and the need to maintain consistent product quality further reinforce the importance of specialized biological safety assessments in this application area.
Cell and gene therapy is expected to be the fastest-growing application segment in the biological safety testing services market, supported by the rapid advancement of highly complex and personalized therapeutic platforms. These products often involve specialized starting materials, viral vectors, living cells, and intricate manufacturing workflows, creating demanding safety and quality assessment requirements. As development programs move toward clinical and commercial stages, the need for robust testing strategies becomes increasingly important. Expanding investment in advanced therapies and the growing focus on demonstrating product consistency are expected to further accelerate demand for specialized safety testing services.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| End-use | Biopharmaceutical Companies, Pharmaceutical Companies, Academic and Research Institutions, Others | Biopharmaceutical Companies | Academic and Research Institutions |
| Application | Vaccine & Therapeutics, Cell and Gene Therapy, Blood & Blood Products, Tissue & Tissue-based Products, Others | Vaccine & Therapeutics | Cell and Gene Therapy |
| Services | Bioburden Testing Services, Endotoxin Testing Services, Sterility Testing Services, Viral Clearance and Validation Services, Cell Line Authentication and Characterization Tests, Residual Host Contamination Testing Services, Adventitious Agent Detection Testing Services, Others | Bioburden Testing Services | Cell Line Authentication and Characterization Tests |
Competitive Landscape and Market Positioning
Leading companies in the biological safety testing services market:
1. Charles River Laboratories International Inc. (United States)
2. Lonza Group AG (Switzerland)
3. Thermo Fisher Scientific Inc. (United States)
4. Merck KGaA (Germany)
5. Eurofins Scientific SE (Luxembourg)
6. SGS SA (Switzerland)
7. WuXi AppTec Co. Ltd. (China)
8. Sartorius AG (Germany)
9. bioMérieux SA (France)
10. Toxikon Corporation (United States)
The biological safety testing services market is expanding steadily as regulatory scrutiny surrounding biopharmaceutical quality and product safety intensifies globally. Service providers are incorporating advanced analytical methods, automation technologies, and rapid testing platforms to improve accuracy and turnaround efficiency. Expanding biologics production and increasing outsourcing activity are further driving demand for specialized testing capabilities, supporting continuous growth and service diversification within the market.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories International Inc. (United States) | |||||||
| Lonza Group AG (Switzerland) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Merck KGaA (Germany) | |||||||
| Eurofins Scientific SE (Luxembourg) | |||||||
| SGS SA (Switzerland) | |||||||
| WuXi AppTec Co. Ltd. (China) | |||||||
| Sartorius AG (Germany) | |||||||
| bioMérieux SA (France) | |||||||
| Toxikon Corporation (United States). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| SGS SA | Oct-24 | SGS announced a strategic expansion of its global biopharmaceutical testing capacity to address increasing demand for large-molecule drug development. The initiative enhances the company's end-to-end service offering, including cell bank safety assessment, product characterization, method development, and final product release, strengthening its infrastructure for supporting complex biologic drug development programs from early stage to commercialization. |
| SGS SA | Aug-24 | SGS launched a suite of specialized biopharmaceutical testing services in North America, focusing on large-molecule bioanalysis. This expansion supports the rising demand for pharmacokinetics, immunogenicity, and biomarker analysis required for monoclonal antibodies and cell-based therapies, effectively scaling the company's capability to support clinical-stage biologics and advanced therapeutic pipelines. |
| Charles River Laboratories | May-23 | Charles River Laboratories entered a partnership with Wheeler Bio to establish an embedded "RightSource" quality control laboratory. By integrating GMP-compliant biological safety and QC testing directly within a biomanufacturing facility, the initiative streamlines the development workflow for early-stage biopharmaceutical firms, significantly reducing the time required for testing cycles during the critical transition into clinical trials. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Biological Safety Testing Services Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Testing Phase | Preclinical Testing, Clinical Development Testing, Commercial Manufacturing Testing, Post-Market Testing |
| Outsourcing Model | Fully Outsourced Testing, Partially Outsourced Testing, In-House Testing |
| Service Provider Type | Contract Testing Organizations, Pharmaceutical & Biopharmaceutical Service Providers, Academic & Research Laboratories, Independent Specialized Laboratories |
Biological Safety Testing Services Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Biopharmaceutical Outsourcing Strategy Assessment |
|
| Advanced Therapy Testing Opportunity Assessment |
|
| Client Decision-Making and Vendor Selection Criteria |
|
Need a different cut of the data?
Request Custom ResearchHow large is the biological safety testing services market?
What is the expected industry size of biological safety testing services by 2036?
How are expanding biologics and biosimilars pipelines impacting demand for biological safety testing services?
How is cell and gene therapy development and outsourcing reshaping biological safety testing demand?
Why are biopharmaceutical companies the largest end users of biological safety testing services?
Why is cell and gene therapy the fastest-growing application segment?
Why does North America dominate biological safety testing services?
What is fueling Asia Pacific’s rapid growth in testing services?
Who holds a significant market share in the biological safety testing services landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization